Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | ESR1 | P03372 | 4/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.30 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.30 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2697473 | 1.00 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL164931 | 1.00 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL11675272 | 1.00 | CYP3A4 (0.75) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL8853066 | 0.97 | CYP3A4 (0.71) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL6939765 | 0.97 | CYP3A4 (0.71) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL561726 | 0.87 | TDP1 (0.86) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL3181354 | 0.87 | TDP1 (0.86) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL9420677 | 0.87 | TDP1 (0.86) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL1951204 | 0.87 | TDP1 (0.86) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL81285 | 0.87 | TDP1 (0.86) | CYP3A4TDP1ESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716466-A | Method for preparing chiral alpha-amino boric acid/boric acid ester through nickel-catalyzed asymmetric hydroamidation | 南京大学 | 2022-07-08 | — | — | CN | claimed |
| US-20030055037-A1 | Benzimidazole and indole derivatives as CRF receptor modulators | NEUROGEN CORPORATION | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055037-A1 | Benzimidazole and indole derivatives as CRF receptor modulators | CRHR1, CRH, HTR4 | CYP3A4 2228/4885TDP1 3664/4885ESR1 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.